TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Study to Evaluate the Efficacy and Safety of Three Different Doses of BAY1817080 Compared to Placebo in Patients With Chronic Cough

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Adults ≥ 18 years of age at the time of signing the informed consent.~* A cough that has lasted for at least 12 months (unresponsive to treatment options) with a diagnosis of refractory chronic cough and/or idiopathic (unexplained) chronic cough.~* Persistent cough for at least the last 8 weeks before screening.~* Women of childbearing potential must agree to use acceptable effective or highly effective birth control methods during the study and for at least 30 days after the last dose.~* Capable of giving signed informed consent.~Exclusion Criteria:~* Smoking history within the last 12 months before screening (all forms of smoking, including e-cigarettes, cannabis and others), and any former smoker with more than 20 pack-years.~* Ongoing or previous exposure to inhalational toxic fumes (e.g., ammonia, chlorine, nitrogen dioxide, phosgene and sulfur dioxide) within the last 12 months before screening.~* Respiratory tract infection within 4 weeks before screening.~* History of chronic bronchitis.~* Systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 100 mmHg at screening visit.~* Positive SARS-CoV-2 virus RNA and/or serology IgG tests at screening visit.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BAY1817080 dose A BID (Type: EXPERIMENTAL): Each participant will be randomized to receive one of three oral doses of BAY 1817080 or placebo, administered twice daily over the course of 12 weeks.
- BAY1817080 dose B BID (Type: EXPERIMENTAL): Each participant will be randomized to receive one of three oral doses of BAY 1817080 or placebo, administered twice daily over the course of 12 weeks.
- BAY1817080 dose C BID (Type: EXPERIMENTAL): Each participant will be randomized to receive one of three oral doses of BAY 1817080 or placebo, administered twice daily over the course of 12 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Each participant will be randomized to receive one of three oral doses of BAY 1817080 or placebo, administered twice daily over the course of 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 3, International, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Trial of Linaclotide Administered Orally for 12 Weeks to Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patient has signed an Informed Consent Form(ICF).~2. Patient Must not be pregnant or breastfeeding and agree to use birth control~3. Patient meets the colonoscopy requirements defined by the American Gastroenterological Association guidelines and no clinically-significant laboratory or physical examination findings;~4. Patient meets protocol-defined criteria for Irritable Bowel Syndrome with Constipation(IBS-C), including stool frequency, straining, stool consistency, abdominal pain, and abdominal discomfort criteria~5. Patient meets protocol-defined eDiary completion Compliance and agrees to refrain from making any new, major life-style changes that may affect IBS-C symptoms~Exclusion Criteria:~1. Recent history of mushy or watery stools~2. Various medical conditions, medical histories, or family medical histories that would not make the patient a good candidate for the study~3. Patient currently has both unexplained and clinically significant alarm symptoms or systemic signs of infection or colitis.~4. Surgery to the gastrointestinal tract~5. Usage of prohibited medications

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- controlled arm (Type: PLACEBO_COMPARATOR): None
- treatment arm (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Randomized Controlled Trial of Wellness Recovery Action Planning

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~* age 18 years or older~* English speaking~* severe mental illness as confirmed by: 1) a Kessler Self-Report Measure (K-6) score of 13 or higher; and/or 2) enrolled as a client of the public mental health system in the state of Ohio.~Exclusion Criteria~* non English speaking~* not meeting clinical criteria for severe mental illness

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Wellness Recovery Action Planning (WRAP) (Type: EXPERIMENTAL): WRAP consists of 8 sessions lasting for 2-½ hours, convened once a week over a period of 8 weeks. Topics include: Introduction to WRAP, Developing a Wellness Toolbox, Creating a Daily Maintenance Plan, Identifying Triggers, Identifying Early Warning Signs, Managing When Things Break Down, and Crisis Planning. Coursework is interactive, using lecture, question and answer, group discussion, and individual or group exercises. Each session includes a lecture on recovery topics such as self-esteem, changing negative thoughts to positive ones, peer support, and lifestyle issues.
- Comparison Wait-List Group (Type: NO_INTERVENTION): Participants assigned to the comparison group were in a delayed treatment condition in which they continued in public services as usual, but were offered the chance to attend WRAP groups after their final research interview.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Extension Study to Provide Continued Bevacizumab Therapy to Participants With Solid Tumors Who Were Previously Enrolled in a Roche/Genentech Sponsored Study

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Participant is treated with bevacizumab at the end of the Roche/Genentech sponsored parent trial and continues to have benefit as judged by the investigator~* Eligible for continuation of bevacizumab treatment at the end of a parent trial, according to parent trial protocol~* Able to comply with this extension study protocol (MO25757)~Exclusion Criteria:~* Evidence of disease progression assessed according to parent trial protocol during the screening phase for this extension study~* Evidence of any adverse event potentially attributable to bevacizumab, for which the local label recommends permanent discontinuation~* A treatment interruption with bevacizumab of more than 42 days since the last administration of bevacizumab in the parent trial~* Evidence of any other disease that would put the participant at high risk for treatment-related complications

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Breast Cancer (Type: EXPERIMENTAL): Participants will receive bevacizumab until progression of disease or unacceptable toxicity, withdrawal of consent or death whichever occurs first.
- Ovarian Cancer or Peritoneal Carcinoma (Type: EXPERIMENTAL): Participants will receive bevacizumab until progression of disease or unacceptable toxicity, withdrawal of consent or death whichever occurs first.
- Renal Cell Carcinoma (Type: EXPERIMENTAL): Participants will receive bevacizumab until progression of disease or unacceptable toxicity, withdrawal of consent or death whichever occurs first.
- Colorectal Cancer (Type: EXPERIMENTAL): Participants will receive bevacizumab until progression of disease or unacceptable toxicity, withdrawal of consent or death whichever occurs first.
- Non-Squamous, Non-Small Cell Lung Cancer (Type: EXPERIMENTAL): Participants will receive bevacizumab until progression of disease or unacceptable toxicity, withdrawal of consent or death whichever occurs first.
- Glioblastoma Multiforme (Type: EXPERIMENTAL): Participants will receive bevacizumab until progression of disease or unacceptable toxicity, withdrawal of consent or death whichever occurs first.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Combivir And Maraviroc In Antiretroviral Naive Subjects In Russia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Over 18 years of age.~* R5 HIV infection on screening tropism test.~* Viral load \>1,000 copies/mL.~* Never previously treated with anti-HIV medicines.~Exclusion Criteria:~* Previously treated with anti-HIV medicines.~* Hepatitis B co-infection.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: EXPERIMENTAL): Single arm study of combivir and maraviroc for 48 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Management of Diabetes in the Emergency Room: a Randomized Trial of an Insulin Protocol.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 18-80 years~2. History of type 2 diabetes mellitus for at least 3 months~3. Prior therapy with dietary management, oral agents, or insulin~4. Non child-bearing potential or a negative urine pregnancy test~5. Initial blood glucose in ER \> 200 mg/dl~Exclusion Criteria:~1. Subsequent finding of diabetic ketoacidosis or hyperosmolar non-ketotic syndrome after initial evaluation.~2. Patients with critical illness suspected to require intensive care unit admission or direct surgical intervention.~3. History of current drug or alcohol abuse.~4. History of current mental illness~5. Inability to give informed consent~6. Female patients who are pregnant or are breast feeding~7. Patients who have clinically significant liver disease with AST/ALT (aspartate transaminase/alanine transaminase) \> 3 times the upper range of normal~8. Patients currently treated with dialysis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- aspart detemir (Type: ACTIVE_COMPARATOR): these subjects will be treated with insulin aspart every 2 hours if blood glucose is more than 200 mg/dl during their ER evaluation. If they are admitted to hospital then they will receive a weight-based dose of insulin detemir immediately prior to admission and then every 24 hours thereafter combined with mealtime doses of insulin aspart if they are eating.
- usual care (Type: NO_INTERVENTION): these subjects will receive no insulin per protocol during their ER stay or during a possible inpatient admission. The care for their diabetes will be solely determined by the physician(s) in the ER and by the physician(s) caring for them in the hospital if they are admitted. They may receive no therapy, oral agents or insulin per primary physician preference.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: COVID-19 Risk Reduction Among African American Parishioners

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* African American older adults aged 55 years with a chronic medical condition or 65years and older~* Have at least one risk factor for COVID-19~Exclusion Criteria:~* Resident of care facility~* Cognitive deficit (identified by short version of mini-mental instrument)~* Does not self-identify as African American and/or Black~* Under the age of 55years~* Unable to speak and/or read English

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Risk Reduction of COVID-19 Among African American Parishioners (Type: EXPERIMENTAL): This arm will implement one group pretest-posttest design to improve COVID associated health outcomes of AA older parishioners in collaboration with trained young church-based health educators.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical and Economic Outcomes of Patients Utilizing Combination Therapy for Enlarged Prostates: A Henry Ford Database Assessment

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Males~* aged 50 years or older~* medical claim of EP~* prescription claim(s) for either a 5ARI or both 5ARI and AB (provided both are within 180 days of index date)~* continuously eligible for 3 months prior to and at least 5 months after their index prescription date.~Exclusion Criteria:~* Patients with prostate or bladder cancer~* any prostate-related surgical procedure within 5 months of index date~* prescription claim for finasteride indicative of male pattern baldness; AB monotherapy only; initiation of 5ARI occurring more than 180 days after initiation of AB

- Gender: MALE
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Early 5ARI Initiation (Type: None): Patients with EP receiving either 5ARI monotherapy or combination therapy (AB + 5ARI) with early initiation of 5ARI (within 30 days of initiation of AB)
- Late 5ARI Initiation (Type: None): Patients with EP receiving combination therapy (AB + 5ARI) with late initiation of 5ARI (within 31 to 180 days after initiation of AB)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients With Metastatic Colorectal Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients ≥ 18 years of age.~* Metastatic colorectal cancer.~* ≥ 1 target lesion.~Exclusion Criteria:~* Previous treatment with oxaliplatin or bevacizumab.~* Previous systemic chemotherapy or immunotherapy for advanced or metastatic disease.~* Progressive disease during or within 6 months of completion of previous adjuvant therapy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- XELOX (oxaliplatin+capecitabine) (Type: EXPERIMENTAL): Patients in the 2-arm part of the study received oxaliplatin 130 mg/m\^2 intravenously (iv) on Day 1 of every 3 week cycle + capecitabine 1000 mg/m\^2 orally twice a day for the first 2 weeks of every 3 week cycle. Patients in the 4-arm part of the study received the same treatments plus placebo for bevacizumab 7.5 mg/kg iv on Day 1 of every 3 week cycle.
- XELOX (oxaliplatin+capecitabine) + bevacizumab (Type: EXPERIMENTAL): Patients in the 4-arm part of the study received oxaliplatin 130 mg/m\^2 intravenously (iv) on Day 1 of every 3 week cycle + capecitabine 1000 mg/m\^2 orally twice a day for the first 2 weeks of every 3 week cycle + bevacizumab 7.5 mg/kg iv on Day 1 of every 3 week cycle.
- FOLFOX-4 (oxaliplatin+leucovorin+fluorouracil) (Type: ACTIVE_COMPARATOR): Patients in the 2-arm part of the study received oxaliplatin 85 mg/m\^2 intravenously (iv) + leucovorin 200 mg/m\^2 iv on Day 1 of every 2 week cycle + fluorouracil 400 mg/m\^2 bolus injection over 2 to 4 min followed by 600 mg/m\^2 continuous infusion over 22 h on Days 1 and 2 of every 2 week cycle. Patients in the 4-arm part of the study received the same treatments plus placebo for bevacizumab 5 mg/kg iv on Day 1 of every 2 week cycle.
- FOLFOX-4 (oxaliplatin+leucovorin+fluorouracil) + bevacizumab (Type: ACTIVE_COMPARATOR): Patients in the 4-arm part of the study received oxaliplatin 85 mg/m\^2 intravenously (iv) + leucovorin 200 mg/m\^2 iv + bevacizumab 5 mg/kg iv on Day 1 of every 2 week cycle + fluorouracil 400 mg/m\^2 bolus injection over 2 to 4 min followed by 600 mg/m\^2 continuous infusion over 22 h on Days 1 and 2 of every 2 week cycle.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Randomized, Multicenter, Open-label, Parallel-group, 12-week Study to Assess the Efficacy and Safety of Switching From Tiotropium to QVA149 (Indacaterol Maleate/Glycopyrronium Bromide) in Symptomatic Mild to Moderate COPD Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed diagnosis of COPD and post-bronchodilator FEV1 ≥ 50% of the predicted normal value and post-bronchodilator FEV1/FVC \< 0.7 (COPD Grade 1 or 2 by severity of airflow limitation (GOLD 2015)~* Patients with CAT score ≥ 10 at Visit 0 and Visit 1.~* Patients who are on and have been on tiotropium monotherapy for the past 3 months.~* 0 or 1 COPD exacerbation in the previous 12 months (not leading to hospital admission).~Exclusion Criteria:~* Treatment with any inhaled corticosteroid (ICS) in the 3 months prior to Visit 1.~* COPD exacerbation between Visit 0 and 1.~* Patients with concomitant pulmonary disease~* Patients with a history of respiratory infection within 4 weeks prior to Visit 0.~* Prior or current diagnosis of asthma.~* Presence of any contraindication, warning, precaution, hypersensitivity to LABA and LAMA~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Indacaterol and glycopyrronium (QVA149) (Type: EXPERIMENTAL): QVA149 110/50 μg capsules for inhalation delivered once daily via single-dose dry powder inhaler (SDPPI) for 12 weeks
- Tiotropium (Type: ACTIVE_COMPARATOR): Tiotropium 18 μg capsules for inhalation delivered once daily via HandiHaler® device for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Companion: Sensor-based Two-way Communication for Physical Activity in Older Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 60 years and above- This intervention study focusses on this population demographic.~* Participants have a body mass index greater than 25 kg/m2- This threshold for BMI is used to classify an adult as overweight or obese~* No conditions preventing participation in physical activity lasting 10 to 30 min- Such conditions will limit prescription of physical activity/exercise components of the training program and that promoted using Companion.~* Have a smart phone- The absence of a smart phone will limit the ability of remote communication with the study participant using Companion.~Exclusion Criteria:~* Engage in structured physical activity for more than 2 days/week lasting 30 min/session- Physically active participants will not be representative of typical adults \>60 y. Being active prior to study participation may mask the effects of the intervention.~* Regularly use any assistive device for walking- Use of an assistive device would limit the ability to engage in prescribed physical activity. Future work can be tailored for sub-groups in the demographic being studied.~* Likely to alter medications pertaining to cardiovascular or metabolic health- Altering medications during the study will influence change in selected outcome measures.

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: 90 Years
- Healthy Volunteers: t

Study Arms:
- Control (Type: NO_INTERVENTION): Control group will engage in a 16-week supervised exercise program and then be followed-up after 24 weeks
- Treatment (Type: EXPERIMENTAL): Treatment group will engage in a 16-week supervised exercise program and then be followed-up after 24 weeks. In addition, the Companion will be deployed in the treatment group only.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Sublingual Immunotherapy (SLIT) Tablets in Grass Pollen Rhinoconjunctivitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Written consent~* Grass-pollen related allergic rhinoconjunctivitis for at least the last 2 pollen seasons.~* Sensitised to grass pollen (positive SPT and RAST level of at least class 2).~* Total symptom score of the RRTSS during the previous pollen season greater than or equal to 12.~* Safety laboratory resuts within the references ranges~Exclusion Criteria:~* Pregnancy, breast-feeding/lactation~* Had received desensitisation treatment for grass pollen~* Treatment by immunotherapy with another allergen within the previous 5 years~* Usual contraindications of immunotherapy such as serious immunopathologic conditions or malignancies~* Treated with beta-blockers or under continuous corticotherapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- 100 IR (Type: EXPERIMENTAL): 100 IR grass pollen allergen extract tablet
- 300 IR (Type: EXPERIMENTAL): 300 IR grass pollen allergen extract tablet
- 500 IR (Type: EXPERIMENTAL): 500 IR grass pollen allergen extract tablet
- Placebo (Type: PLACEBO_COMPARATOR): Placebo tablet

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete